Modified T cells could treat multiple myeloma, study finds

05/12/2014 | Science World Report

Genetically modified T lymphocytes can effectively recognize the molecule CS1, which is present in more than 95% of myeloma cells, and help the body's immune system eradicate the cells, according to researchers from the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The modified T cells can be reproduced in the lab and can potentially replicate in the body to stop tumor growth and prevent relapse for a greater period of time than current myeloma treatments. The study appeared in the journal Clinical Cancer Research.

View Full Article in:

Science World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA